Drug Profile
Research programme: G protein-coupled receptor modulating small molecules - Omeros Corporation
Latest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator Omeros Corporation
- Class Analgesics; Antineoplastics; Antivirals; Obesity therapies; Osteoporosis therapies; Small molecules
- Mechanism of Action G protein-coupled receptor modulators; Neuromedin U receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- No development reported Autistic disorder; Cognition disorders; Demyelinating disorders; Eating disorders; Epstein-Barr virus infections; Gastrointestinal disorders; Inflammation; Metabolic disorders; Multiple sclerosis; Obesity; Osteoporosis; Pain; Psychotic disorders; Rheumatoid arthritis; Sleep disorders
Most Recent Events
- 18 Mar 2022 Preclinical trials in Cancer in USA (Omeros Corporation SEC filing, Form 10-K, March 2022)
- 04 Sep 2020 No development reported - Preclinical for Cancer in USA (unspecified route) (Omeros Corporation pipeline, September 2020)
- 04 Sep 2020 No development reported - Preclinical for Eating disorders in USA (unspecified route) (Omeros Corporation pipeline, September 2020)